Articles scientifiques

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Auteurs : Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H
Année : 2011
Journal : Lancet Oncol
Volume : 12(12)
Pages : 1134-42

Prevention of febrile neutropenia in chemotherapy – treated cancer patients : Pegylated versus standard myeloid colony stimulating factors. Do we have a choice ?

Auteurs : Klastersky J, Awada A
Année : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(1)
Pages : 17-23

Pattern of care in locally advanced breast cancer: focus on local therapy.

Auteurs : Sinacki M, Badzio A, Welnicka-Jaskiewicz M, Bogaerts J, Piccart-Gebhart M, Therasse P, Smith IE, Hatschek T, Jassem J
Année : 2011
Journal : Breast
Volume : 20(2)
Pages : 145-50

Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.

Auteurs : Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart-Gebhart M, Sotiriou C
Année : 2011
Journal : Endocr Relat Cancer
Volume : 18(6)
Pages : 721-30

Is VEGF a predictive biomarker to anti-angiogenic therapy ?

Auteurs : Otrock ZK, Hatoum HA, Musallam KM, Awada A, Shamseddine AI
Année : 2011
Journal : Crit Rev Oncol Hematol
Volume : 79(2)
Pages : 103-11

A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.

Auteurs : Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F
Année : 2011
Journal : BJU Int
Volume : 108(5)
Pages : 679-686

Multiple-input multiple-output causal strategies for gene selection.

Auteurs : Bontempi G, Haibe-Kains B, Desmedt C, Sotiriou C, Quackenbush J
Année : 2011
Journal : BMC Bioinformatics
Volume : 12(1)
Pages : 458

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.

Auteurs : Mattarollo SR, Loi S, Duret H, Zitvogel L, Smyth MJ
Année : 2011
Journal : Cancer Res
Volume : 71(14)
Pages : 4809-20

Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study.

Auteurs : Vos B, Rozema T, Miller RC, Hendlisz A, Van Laethem JL, Khanfir K, Weber DC, El Nakadi I, Van Houtte P
Année : 2011
Journal : Dis. Esophagus
Volume : 24(4)
Pages : 258-64

DNA methylation profiling reveals a predominant immune component in breast cancers.

Auteurs : Dedeurwaerder S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Defrance M, Michiels S, Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, van Baren N, Coulie PG, Piccart-Gebhart M, Sotiriou C, Fuks F
Année : 2011
Journal : EMBO Mol Med
Volume : 3(12)
Pages : 726-41

Pappillary serous carcinoma of the peritoneum after risk reducing salpingo-oophorectomy (RRSO) in women with BRCA1 mutation.''

Auteurs : Vanderbeeken MC, Schöffski P, Wildiers H
Année : 2011
Journal : Belgian J Medical Oncology
Volume : 5
Pages : 2

A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.

Auteurs : Heath EI, Lorusso P, Ramalingam SS, Awada A, Egorin MJ, Besse-Hamer T, Cardoso F, Valdivieso M, Has T, Alland L, Zhou X, Belani CP
Année : 2011
Journal : Invest New Drugs
Volume : 29(6)
Pages : 1426-31

mTor inhibition in RCC: proof of concept, clinical use, and future directions,

Auteurs : Aftimos P, Awada A, Gil T
Année : 2011
Journal : Belgian J Medical Oncology
Volume : 5(5)
Pages : 205-11

Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis.

Auteurs : Bidard FC, Lossignol D, Larsimont D, Piccart-Gebhart M, Awada A
Année : 2011
Journal : Ann Oncol
Volume : 22(2)
Pages : 480-2

Neoadjuvant chemotherapy and targeted therapies: a promising strategy.

Auteurs : Metzger-Filho O, de Azambuja E
Année : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pages : 116-9

Strategies for subtypes – dealing with the diversity of breast cancer:Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early breast cancer 2011.(+ Panel Members)

Auteurs : Goldhirsch A, Wood WC, Coates AS, Gelber Rd, Thurliman B, Senn HJ, + collaborators (among others :, Piccart-Gebhart M
Année : 2011
Journal : Ann Oncol
Volume : 22(8)
Pages : 1736-47

Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?

Auteurs : Klastersky J, Awada A
Année : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(1)
Pages : 17-23

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

Auteurs : Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G
Année : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pages : 147-51

Prevention of neutropenia-related events in elderly patients with haematological cancer

Auteurs : Klastersky J, Gombos A, Georgala A, Awada A
Année : 2011
Journal : Aging Health
Volume : 7(6)
Pages : 829-42

Febrile neutropenia: a critical review of the initial management.

Auteurs : Klastersky J, Awada A, Paesmans M, Aoun M
Année : 2011
Journal : Crit Rev Oncol Hematol
Volume : 78(3)
Pages : 185-94